
    
      Full Analysis Population 1: Defined as all subjects who are randomized, vaccinated, and
      provide at least one day of complete data on the symptom diary.

      Full Analysis Population 2: Defined as all subjects who are randomized and vaccinated.

      Immunogenicity Population: Defined as subjects who received vaccine, provided baseline and
      Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame
      with no protocol violations affecting immunogenicity.
    
  